Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,728 across all filing types
Latest filing 2013-07-03 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
2013年上半年度业绩提示性公告
Regulatory Filings Classification · 95% confidence The document is a performance forecast announcement for the first half of 2013, indicating expected net profit growth and referencing that detailed data will be disclosed in the 2013 half-year report. It explicitly states that the forecast has not been audited by a registered accountant. The document is short (566 characters) and serves as a preliminary earnings guidance rather than a full financial report. It does not contain actual financial statements or detailed analysis, so it is not an Interim/Quarterly Report (IR). It is also not an Earnings Release (ER) since it provides a forecast rather than actual results. The document is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement of expected performance without substantive financial data or full report content.
2013-07-03 Chinese
增发A股网上路演公告
Capital/Financing Update Classification · 100% confidence The document is an announcement regarding an online roadshow for a public offering of additional A shares by Kunming Pharmaceutical Group Co., Ltd. It mentions the approval of the issuance plan by the China Securities Regulatory Commission and provides details about the roadshow event for investors. The content focuses on financing activities and investor communication related to a capital increase. The document length is short (590 characters) and it is not a full financial report but an update on financing activity. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2013-07-02 Chinese
增发招股意向书摘要
Capital/Financing Update Classification · 95% confidence The document is titled as an "增发 A 股申请文件 招股意向书摘要" which translates to "Application document for additional issuance of A shares - Prospectus summary." It contains detailed information about the company's share issuance plan, including the number of shares to be issued, pricing, underwriting, use of proceeds, major shareholders, financial data for the past three years, and management discussion and analysis. The document is clearly related to a capital raising event through a public offering of shares (增发 A 股). It includes detailed financial statements and investment project descriptions related to the use of the raised funds. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document is not an annual report, audit report, or earnings release, but specifically a financing-related filing. Therefore, the correct classification is CAP with high confidence.
2013-07-02 Chinese
增发A股网下发行公告
Capital/Financing Update Classification · 100% confidence The document is a detailed announcement regarding the issuance of additional A shares by Kunming Pharmaceutical Group Co., Ltd. It includes specifics about the number of shares, pricing, subscription procedures, underwriting, important dates, and legal compliance. The text references regulatory approval by the China Securities Regulatory Commission and the Shanghai Stock Exchange. It is not a financial report, earnings release, or management discussion but rather a formal announcement about a capital raising event through share issuance. The document is lengthy (over 10,000 characters) and contains detailed procedural and regulatory information about the share issuance. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2013-07-02 Chinese
增发A股网上发行公告
Capital/Financing Update Classification · 100% confidence The document is an announcement regarding the public offering of additional A shares by Kunming Pharmaceutical Group Co., Ltd. It details the issuance quantity, pricing, subscription procedures, allocation methods, important dates, and other related information about the share issuance. It is not a financial report, earnings release, or management discussion but rather a formal announcement about a capital raising event through share issuance. The document includes terms like '增发' (additional issuance), '发行价格' (issue price), '申购' (subscription), and '配售' (allocation), which are typical for capital/financing updates. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length is sufficient and contains detailed information about the issuance, not just a brief notice or a report publication announcement.
2013-07-02 Chinese
公开发行A股招股意向书
Capital/Financing Update Classification · 95% confidence The document is titled as "昆明制药增发 A 股申请文件 招股意向书" which translates to "Kunming Pharmaceutical Additional A Share Issuance Application Document Prospectus." It contains detailed information about the company's share issuance plan, including stock code, stock abbreviation, company basic information, issuance details, pricing, expected fundraising amount, use of proceeds, dividend policy, risk factors, company structure, financial data, and management discussion. The document is lengthy (15,000 characters) and includes comprehensive financial and operational data related to a capital raising event. This matches the characteristics of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising and financing activities. It is not an Annual Report or Interim Report as it focuses on share issuance and fundraising, nor is it a simple announcement or regulatory filing. Therefore, the correct classification is CAP with high confidence.
2013-07-02 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.